IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Essen Biotech
Dana-Farber Cancer Institute
Hadassah Medical Organization
Medicenna Therapeutics, Inc.
Vall d'Hebron Institute of Oncology
Erasmus Medical Center
Sheba Medical Center